Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

IPAH disease worsening linked to 2 tumor biomarkers: Study

Elevated levels of two tumor biomarkers, AFP and CA125, were found to predict disease worsening in people with idiopathic pulmonary arterial hypertension (IPAH) in a new study from China. “Changes in AFP over time serve as an indicator of disease alteration, enabling detection of disease progression or treatment response,”…

Delayed diagnosis common with PAH, multinational survey finds

About 41% of pulmonary arterial hypertension (PAH) patients in a multinational survey were initially misdiagnosed, seeing an average of 2.9 physicians before getting their correct diagnosis. The non-specific nature of their disease symptoms and a lack of awareness among patients and primary care physicians contribute to this delay,…

Algorithm may help diagnose PH when echocardiography uncertain

An algorithm based on artificial intelligence (AI) and machine learning may help in diagnosing pulmonary hypertension (PH), a new study shows. Its findings are particularly important for people suspected of having PH but whose disease remains uncertain using echocardiography, a noninvasive imaging method to examine heart structure and function.

Novel cell therapy CAP-1002 safe, shows promise in PAH: Trial

In people with pulmonary arterial hypertension (PAH), treatment with the novel cell therapy CAP-1002 was safe and showed encouraging efficacy, according to the results of a Phase 1a/b clinical trial. In particular, exploratory efficacy measures supported the potential of CAP-1002 in improving cardiopulmonary function, including exercise capacity, in PAH…

A Conversation With Rare Disease Advocates